← Back to Search

Monoclonal Antibodies

Balstilimab for Cervical Cancer

Phase 2
Waitlist Available
Research Sponsored by Agenus Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.

Eligible Conditions
  • Cervical Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Group I: Balstilimab + ZalifrelimabExperimental Treatment1 Intervention
Balstilimab in combination with Zalifrelimab (combination therapy): approximately 30 patients.
Group II: BalstilimabExperimental Treatment1 Intervention
Balstilimab monotherapy: approximately 147 patients.

Find a Location

Who is running the clinical trial?

Agenus Inc.Lead Sponsor
52 Previous Clinical Trials
4,816 Total Patients Enrolled
Betta Pharmaceuticals Co., Ltd.Industry Sponsor
77 Previous Clinical Trials
9,538 Total Patients Enrolled
Medical DirectorStudy DirectorAgenus Inc.
2,834 Previous Clinical Trials
8,079,780 Total Patients Enrolled
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top